Abstract Details

Title Iron Content in Benign and Non-Benign Patients with Relapsing-Remitting Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P06 - (-)

Poster/Presentation
Number 108

Objective

Background BACKGROUND: BMS patients exhibit a low disability in the clinical course of MS. Abnormal iron concentration in the SDGM structures of MS patients has been associated with atrophy, disease duration, disability and cognitive dysfunction.

Design/Methods DESIGN/METHODS: Susceptibility-weighted imaging (SWI)-filtered phase images were acquired on a 3T MRI in 37 BMS patients (Expanded Disability Status Scale, EDSS score ? 2 and disease duration ? 15 years), 49 non-BMS RR patients (EDSS score > 2 and disease duration ? 15 years) and 76 age- and sex-matched healthy controls (HC). Conventional MRI brain lesion and atrophy, and SDGM volume and iron outcomes were assessed in all subjects.

Results RESULTS: Non-BMS RR group had higher EDSS score compared to the BMS (3.9 vs. 1.9, p<0.001). Both non-BMS RR and BMS patients showed significantly higher number and volume of T2 lesions and lower whole brain, gray matter and white matter volumes compared to HC (p<0.001). Non-BMS RR patients showed significantly higher iron concentration in the thalamus, total SDGM and red nucleus (p<0.01), and trend for higher iron concentration in the pulvinar nucleus and amygdala, compared to HC (p<0.05). On the contrary, BMS group did not significantly differ from HC in iron content. No differences between BMS and non-BMS RR patients were found in brain lesion and atrophy outcomes. While, non-BMS RR patients showed increased iron content compared to BMS patients, these differences did not reach statistical significance.

Conclusions CONCLUSIONS: This study shows that increased iron concentration in SDGM may play an important role in defining BMS vs. non-BMS disease phenotype. Further studies are needed to elucidate the role of increased iron content for disability progression in MS.

Authors/Disclosures
Tina Foster PRESENTER	No disclosure on file
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo)	Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Jesper Hagemeier	No disclosure on file
Ellen Carl, MS (The Jacobs Neurological Institute)	No disclosure on file
David Hojnacki, MD, FAAN (University At Buffalo, Jacobs Neurological Institute)	Dr. Hojnacki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Hojnacki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Hojnacki has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
Michael G. Dwyer III, MD, PhD (Buffalo Neurological Analysis Center)	Dr. Dwyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Keystone Heart, Ltd. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Dwyer has received research support from Novartis. The institution of Dr. Dwyer has received research support from Keystone Heart, Ltd. The institution of Dr. Dwyer has received research support from Bristol Myers Squibb. The institution of Dr. Dwyer has received research support from Roche.
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo)	Prof. Bergsland has nothing to disclose.
Christopher Magnano (The Jacobs Neurological Institute)	No disclosure on file
Mari Heininen-Brown, BA (The Jacobs Neurological Institute)	No disclosure on file
	No disclosure on file
Howard L. Weiner, MD (Brigham and Women'S Hospital)	Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center)	The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.

��ɫ��

��ɫ��